Chiasso, Switzerland, December 4th, 2024 | Dipharma SA, a pharmaceutical company specialized in high quality and improved medicines for rare diseases, has been recently recognized for the third time as one of the best places to work in Switzerland...

Chiasso, Switzerland, November 6th, 2023 | Dipharma SA, a pharmaceutical company specialized in high quality and improved medicines for rare diseases, has been recently recognized for the second time as one of the best places to work in Switzerlan...

Chiasso, Switzerland and Reading, England, October 4th, 2023 – Dipharma SA (“Dipharma”) and LogixX Pharma (“LogixX”) are delighted to announce the official launch of Sapropterin Dihydrochloride (“Sapropterin”) in the United Kingdom. Sapropterin Di...

Chiasso, Switzerland, July 3rd, 2023 – Dipharma SA (“Dipharma”) today announced that its product Sapropterin Dipharma is now available in main European Countries and in Switzerland. Sapropterin Dipharma is available in the form of soluble ta...

Chiasso, Switzerland and Reading, England, June 27, 2023 – Dipharma SA (“Dipharma”) and LogixX Pharma (“LogixX”) are pleased to announce that the Medicines and Healthcare Products Regulatory Agency (“MHRA”) has granted Marketing Authorization for ...

Princeton, NJ and Chiasso, Switzerland, May 31 st , 2023 – Analog Pharma (member of Duchesnay Pharmaceutical Group, hereafter “Analog”) and Dipharma S.A. (“Dipharma”) are pleased to announce that their 20 mg nitisinone abbreviated new drug applica...

Chiasso, September 15th, 2022 | Dipharma SA, a specialty pharmaceutical company specialized in high quality and improved medicines for rare diseases, has been recently recognized as one of the best places to work for in Switzerland. During the ass...

Rosemont, PA and Chiasso, Switzerland, June 21st, 2022 – Analog Pharma (“Analog”) and Dipharma S.A. (“Dipharma”) today announced that their nitisinone abbreviated new drug application (ANDA) has received final approval from the U.S. Food and Drug ...

Der Gründer und Vorstandsvorsitzende Herr Marc-Olivier Geinoz erläutert, warum sich das Unternehmen für den weitgehend unerforschten Bereich der Generika für seltene Krankheiten entschieden hat und welche Chancen sich bei Stoffwechselkrankheiten b...

Chiasso, Switzerland, February 16th, 2021 – Swiss-based Dipharma S.A. (“Dipharma”) today announced that its proprietary product Miglustat Dipharma 100 mg capsules is now available in Switzerland. Miglustat Dipharma, a generic equivalent to Actelio...